Clinical Trials in Phoenix

Showing 15741-15760 of 16,646 trials

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

NCT00492284

The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.

Choroidal NeovascularizationMacular Degeneration

QLT Inc.162 participantsStarted Jul 2007

Mobile, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +23 more locations

TERMINATEDPhase 1/2< 1 mile

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00090532

AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.

Age-Related Macular Degeneration

Pfizer155 participantsStarted Jan 2004

Mesa, Arizona, United States • Oro Valley, Arizona, United States • Phoenix, Arizona, United States +36 more locations

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Find Trials by Condition in Phoenix

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

PR104 and G-CSF in Treating Patients With Solid Tumors

MMF Influence on HCV Viral Evolution After Liver Transplantation

Gastric Motor Function Measurement in Dyspepsia and Normal Subjects

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

Discharge ALERT: Quality Improvement Initiative

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Registry Experience at the Washington Hospital Center, Des - Taxus Liberte Versus Xience V